Boehringer Ingelheim Marks Great Progress in Immuno-oncology Research Partnerships in 2017
2017 marks a year of significant advancement for Boehringer Ingelheim as it secured a range of external partnerships with the goal of transforming the lives of patients and winning the fight against cancer. External partnerships complement Boehringer Ingelheim’s two-pronged research strategy – investigating both cancer cell-directed therapies and immune cell-directed therapies. This multi-faceted approach offers the potential to bring innovative opportunities to the Boehringer Ingelheim oncology portfolio and novel therapies to patients.
“Immuno-oncology is radically shifting the research and treatment landscape in oncology. We believe that the greatest success in difficult-to-treat cancers will be achieved with immuno-oncology and its combination with cancer cell directed therapy, which is why we are committing significant resources in both areas,” said Jonathon Sedgwick, Ph.D., Vice President and Global Head, Cancer Immunology and Immune Modulation. “In the immuno-oncology space, Boehringer Ingelheim is poised for the next wave of innovation with clinical phase projects ranging across checkpoint inhibitors, oncolytic viruses, cancer vaccines and T-cell engagers. As such, the expansion of our external partnerships is designed to complement our own R&D, push boundaries and foster innovation – all with the goal of bringing medicines of high therapeutic value to patients sooner.”
With approximately 50 percent of its overall early-to-mid-stage pipeline emerging from collaborations, the company’s research strategy is firmly anchored in external innovation for all therapeutic areas, and the breadth and depth of exploration demonstrates Boehringer Ingelheim’s commitment to oncology, including the comprehensive oncology pipeline that encompasses more than 10 clinical stage assets in development for various cancer and tumor types. This is supplemented by the ongoing Corporate Venture Fund activities, which continue to drive innovation through strategic investments in early-stage science and technology.
Bringing together the most creative minds across public and private institutions, including academia and industry, Boehringer Ingelheim has entered into numerous new external partnerships or expanded existing relationships, many of which are researching oncology. These partnerships cover a range of areas from basic science to clinical development and build on past successes. Over the past year, a number of oncology collaborations relating to immunology have generated excitement and fueled innovation, including:
- University of California at Los Angeles, Los Angeles, CA – This collaboration with UCLA’s Technology Development Group aims to develop a promising vaccine technology platform developed by the research team of Drs. William Gelbart and Charles Knobler based on using the protein shell of a plant virus to deliver a self-replicating RNA vaccine cargo to cancer patients’ antigen-presenting cells, which in turn would direct the immune system to eliminate the cancer.
- Siamab Therapeutics, Newton, MA – This partnership is utilizing Siamab’s proprietary technology platform and aims to identify anti-cancer therapeutics that target tumor associated carbohydrate antigens (TACAs), which are present in the majority of solid tumors including ovarian, pancreatic, prostate, colon, gastric and breast. TACAs that are selectively expressed on cancer and not normal healthy cells represent one way of directing cancer killing therapies.
- AbeXXa Biologics, Arlington, TX and Cambridge, MA – AbeXXa is looking to identify a new series of selective molecular targets for cancer from the many thousands of proteins found on the interior of a tumor cell. This new field of research could potentially result in immunotherapies that prove effective for a broad range of patients. In addition, AbeXXa won the 2016 Boston Innovation Prize sponsored by Boehringer Ingelheim and has also received funding through the Boehringer Ingelheim Venture Fund.
“Boehringer Ingelheim believes partnerships are vital to innovation as it leverages human talent and resources to speed research. We highly value our partners’ creativity and the opportunities and resources they offer as we work together to tackle the biggest challenges in oncology,” said Dr. Jörg Barth, Boehringer Ingelheim’s Therapeutic Area Head Oncology. “We believe the best way to accelerate innovation is by combining our in-house capabilities in collaboration with industry and academia. Winning the fight against cancer will only be achieved with novel approaches and genuine scientific breakthroughs.”
From discovery and development through to commercialization, Boehringer Ingelheim is seeking strong, long-term, innovation partnerships to improve our understanding of cancer and transform patient lives. With long-term exploration and investment in mind, the company works to build relationships based on common goals, mutual trust and commitment that involve a “bench to bedside” method, incorporating extensive resources and professionals ranging from scientists in labs to a global sales force.
NOTES TO EDITORS
About Boehringer Ingelheim
Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. In 2016, Boehringer Ingelheim achieved net sales of around 15.9 billion euros. With more than three billion euros, R&D expenditure corresponds to 19.6 percent of net sales.
Social responsibility comes naturally to Boehringer Ingelheim. That is why the company is involved in social projects such as the “Making More Health” initiative. Boehringer Ingelheim also actively promotes workforce diversity and benefits from its employees’ different experiences and skills. Furthermore, the focus is on environmental protection and sustainability in everything the company does.
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.
Phone: + 1 917-692-0848
Dr. Reinhard Malin
Phone: +49 6132 – 77 90815
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
ABB Showcases World-Leading e-Vehicle Fast Chargers and Launches AI Readiness Index at Hannover22.4.2018 13:00 | Tiedote
ABB spotlighted its world-leading Terra HP family of fast chargers for electric vehicles at Hannover Messe, the biggest global industrial trade fair. By operating at powers of up to 350 kilowatts and adding as much as 300 kilometers of range to an electric vehicle in just 12 minutes, the Terra HP family of chargers have made electric cars more appealing for consumers by enabling them to refresh the batteries in about the same time required for filling up a petrol-powered car. Terra HP chargers are being installed around the world, and they have been selected for use by Electrify America, the biggest electric vehicle infrastructure project to date in the United States. ABB, whose broad array of digitally driven technologies for electric-power management are used by utilities and businesses worldwide, is also a global leader in industrial automation and robots enabled by artificial intelligence (AI). Demonstrating its commitment to helping the international community address the opportun
PSE: APM Forum 2018 Focus on Digitalisation for the Process Industries20.4.2018 18:13 | Tiedote
At the 2018 Advanced Process Modelling (APM) Forum this week, process industry organisations presented on digital design and operations applications ranging from accelerating development of the next generation of pharmaceuticals to realising millions of dollars per year in increased profit for large process plants. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180420005517/en/ Ben Weinstein, head of R&D Product and Process Systems Modeling at Procter & Gamble, delivers the keynote speech on how digital design techniques are used systematically to accelerate innovation in P&G. (Photo: Business Wire) Introducing the conference, Prof. Costas Pantelides, MD of conference host Process Systems Enterprise (PSE), described the current wave of digitalisation as the culmination of many years of advanced modelling and IT development. “This is a time of extraordinary opportunities for the process industries” he said. Keynote speaker Ma
Aperta Provides Electronic Funds Transfer (EFT) in Cayman Islands20.4.2018 17:01 | Tiedote
Once again, the Aperta Active Clearing System (ACS) has delivered the mechanism for a country to implement a world-class electronic payment processing environment to maximize a national payments system’s efficiency, effectiveness, security and control. Aperta partnered with the Cayman Islands ACH Operator (Prism Services (Cayman) Ltd.) and local commercial banks to deliver a new Electronic Funds Transfer system. The old process of banks swapping files in a wide-variety of standards and settling bilaterally has been replaced with a common system and standards, employing international-standard secure file transfer protocol, allowing participants to monitor real time net settlement and collateral positions via a secure portal. The Cayman Islands Automated Clearinghouse (CIACH) links all six of the country’s banks and provides the central clearing and settlement mechanism for banks to exchange direct debit and direct credit transactions seamlessly across the country. It is functionally NAC
FII Tech Growth Invests in SECO20.4.2018 16:39 | Tiedote
FII Tech Growth, a fund managed by Fondo Italiano d’Investimento SGR, announces today its second investment in SECO SpA, one of the European leaders in the embedded electronics market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180420005413/en/ (Photo: SECO) SECO, headquartered in Arezzo, Tuscany, with subsidiaries in the U.S.A., Germany and Taiwan, was founded in 1979 by entrepreneurs Daniele Conti and Luciano Secciani. The company designs and manufactures micro-computers and integrated systems for industrial applications. With more than 250 employees, SECO supports customers with a worldwide presence such as Cimbali, Esaote, Technogym and Vimar, and generated revenue in excess of Euro 50 million in 2017. The ability to offer innovative solutions by using cutting-edge technologies has allowed SECO to grow steadily over time. The company developed a network of collaborations with universities and research centres La Sapi
Schlumberger Announces First-Quarter 2018 Results20.4.2018 14:05 | Tiedote
Schlumberger Limited (NYSE:SLB) today reported results for the first quarter of 2018. (Stated in millions, except per share amounts) Three Months Ended Change Mar. 31, 2018 Dec. 31, 2017 Mar. 31, 2017 Sequential Year-on-year Revenue $7,829 $8,179 $6,894 -4% 14% Pretax operating income $974 $1,155 $757 -16% 29% Pretax operating margin 12.4% 14.1% 11.0% -169 bps 145 bps Net income (loss) - GAAP basis $525 $(2,255) $279 n/m 88% Net income, excluding charges & credits* $525 $668 $347 -21% 51% Diluted EPS (loss per share) - GAAP basis $0.38 $(1.63) $0.20 n/m 90% Diluted EPS, excluding charges & credits* $0.38 $0.48 $0.25 -21% 52% *These are non-GAAP financial measures. See section below entitled "Charges & Credits" for details. n/m = not meaningful Schlumberger Chairman and CEO Paal Kibsgaard commented, “As forecast, our results in the first quarter of 2018 largely reflected transitory factors, with seasonal reductions in activity in the Northern Hemisphere and planned project startup costs
Biogen and Ionis Expand Strategic Collaboration to Develop Drug Candidates for a Broad Range of Neurological Diseases20.4.2018 13:30 | Tiedote
Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals (Nasdaq: IONS) announced today they have expanded their strategic collaboration through a new ten-year collaboration agreement to develop novel antisense drug candidates for a broad range of neurological diseases. This collaboration capitalizes on Biogen’s expertise in neuroscience research and drug development and Ionis’ leadership in RNA targeted therapies with the goal of developing a broad pipeline of investigational therapies. It builds upon a productive collaboration that produced SPINRAZA, the first and only approved treatment for patients with spinal muscular atrophy. Today, April 20, 2018, Biogen and Ionis will host company conference calls and webcasts to discuss the new collaboration. Full webcast details can be found below. Under the terms of the collaboration, Biogen will pay Ionis $1 billion in cash, which will include $625 million to purchase 11,501,153 shares of Ionis common stock at a price of $54.34 per share, at an appr
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme